NASDAQ:ANIP ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis → Top-Secret Government Project Revealed (From Porter & Company) (Ad) Free ANIP Stock Alerts $63.24 -0.97 (-1.51%) (As of 06/13/2024 ET) Add Compare Share Share Today's Range$62.76▼$64.4450-Day Range$60.36▼$68.8252-Week Range$48.20▼$70.81Volume135,728 shsAverage Volume140,266 shsMarket Capitalization$1.33 billionP/E Ratio39.53Dividend YieldN/APrice Target$81.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get ANI Pharmaceuticals alerts: Email Address ANI Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside28.1% Upside$81.00 Price TargetShort InterestHealthy1.62% of Shares Sold ShortDividend StrengthN/ASustainability-2.48Upright™ Environmental ScoreNews Sentiment0.72Based on 8 Articles This WeekInsider TradingSelling Shares$10.21 M Sold Last QuarterProj. Earnings Growth14.07%From $3.34 to $3.81 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.69 out of 5 starsMedical Sector57th out of 917 stocksPharmaceutical Preparations Industry20th out of 431 stocks 3.5 Analyst's Opinion Consensus RatingANI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageANI Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about ANI Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.62% of the outstanding shares of ANI Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ANI Pharmaceuticals has recently increased by 65.90%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldANI Pharmaceuticals does not currently pay a dividend.Dividend GrowthANI Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreANI Pharmaceuticals has received a 36.91% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Beta blockers (C07)", "Macrolides", "Antifungal medication (D01) ", "Cyclophosphamide", and "Calcium channel blockers (C08)" products. See details.Environmental SustainabilityThe Environmental Impact score for ANI Pharmaceuticals is -2.48. Previous Next 2.6 News and Social Media Coverage News SentimentANI Pharmaceuticals has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for ANI Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest2 people have searched for ANIP on MarketBeat in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,214,913.00 in company stock.Percentage Held by Insiders12.70% of the stock of ANI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.05% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ANI Pharmaceuticals' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for ANI Pharmaceuticals are expected to grow by 14.07% in the coming year, from $3.34 to $3.81 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ANI Pharmaceuticals is 39.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.30.Price to Earnings Ratio vs. SectorThe P/E ratio of ANI Pharmaceuticals is 39.53, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 167.79.Price to Book Value per Share RatioANI Pharmaceuticals has a P/B Ratio of 2.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ANI Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyA Silent Invasion of AmericaThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.Go here to see why. About ANI Pharmaceuticals Stock (NASDAQ:ANIP)ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Read More ANIP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANIP Stock News HeadlinesJune 7, 2024 | insidertrades.comOri Gutwerg Sells 2,985 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) StockJune 6, 2024 | insidertrades.comChad Gassert Sells 20,000 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) StockJune 5, 2024 | insidertrades.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Chad Gassert Sells 20,000 SharesMay 23, 2024 | insidertrades.comChristopher Mutz Sells 2,000 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) StockMay 22, 2024 | insidertrades.comMuthusamy Shanmugam Sells 12,855 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) StockMay 18, 2024 | insidertrades.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Renee P. Tannenbaum Sells 2,000 SharesMay 17, 2024 | insidertrades.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Sells $1,101,820.90 in StockMay 14, 2024 | insidertrades.comInsider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells 250 Shares of StockJune 10, 2024 | seekingalpha.comANI Pharmaceuticals Is Undervalued, As Royalty Potential Is OverlookedJune 8, 2024 | americanbankingnews.comStephen P. Carey Sells 5,000 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) StockJune 7, 2024 | americanbankingnews.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Ori Gutwerg Sells 2,985 Shares of StockMay 29, 2024 | globenewswire.comANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare ConferenceMay 20, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)May 20, 2024 | markets.businessinsider.comANI Pharma Launches Kionex Suspension For Oral Or Rectal UseMay 20, 2024 | globenewswire.comANI Pharmaceuticals Announces the Launch of Kionex® SuspensionMay 18, 2024 | finance.yahoo.comDirector Renee Tannenbaum Sells 2,000 Shares of ANI Pharmaceuticals Inc (ANIP)May 16, 2024 | finance.yahoo.comInsider Selling: President & CEO Nikhil Lalwani Sells Shares of ANI Pharmaceuticals Inc (ANIP)May 13, 2024 | finance.yahoo.comANI Pharmaceuticals Inc (ANIP) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ...May 13, 2024 | finance.yahoo.comANI Pharmaceuticals, Inc. Just Beat EPS By 459%: Here's What Analysts Think Will Happen NextMay 11, 2024 | finance.yahoo.comANI Pharmaceuticals First Quarter 2024 Earnings: Beats ExpectationsMay 11, 2024 | finance.yahoo.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comANI Pharmaceuticals Reports Strong Q1 2024 Results, Surpassing Revenue ExpectationsMay 10, 2024 | finanznachrichten.deANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 GuidanceMay 10, 2024 | sfgate.comANI: Q1 Earnings SnapshotMay 10, 2024 | markets.businessinsider.comANI Pharmaceuticals, Inc. Q1 Profit Increases, Beats EstimatesSee More Headlines Receive ANIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today6/13/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ANIP Previous SymbolNASDAQ:BPAX CUSIPN/A CIK1023024 Webwww.anipharmaceuticals.com Phone(218) 634-3500Fax218-634-3540Employees642Year FoundedN/APrice Target and Rating Average Stock Price Target$81.00 High Stock Price Target$87.00 Low Stock Price Target$77.00 Potential Upside/Downside+28.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$1.60 Trailing P/E Ratio39.53 Forward P/E Ratio18.93 P/E GrowthN/ANet Income$18.78 million Net Margins6.87% Pretax Margin8.32% Return on Equity17.15% Return on Assets8.29% Debt Debt-to-Equity Ratio0.63 Current Ratio3.95 Quick Ratio3.12 Sales & Book Value Annual Sales$486.82 million Price / Sales2.72 Cash Flow$6.24 per share Price / Cash Flow10.13 Book Value$21.13 per share Price / Book2.99Miscellaneous Outstanding Shares20,970,000Free Float18,309,000Market Cap$1.33 billion OptionableOptionable Beta0.81 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Nikhil Lalwani (Age 46)President, CEO & Director Comp: $2.32MMr. Stephen P. Carey (Age 53)Senior VP of Finance & CFO Comp: $1.11MMr. Chad Gassert (Age 48)Senior Vice President of Corporate Development & Strategy Comp: $849.71kMr. Christopher K. Mutz (Age 52)Senior Vp & Head of Rare Disease Comp: $867.92kMr. Ori Gutwerg (Age 49)Senior Vice President of Generics Comp: $895.16kMr. Muthusamy Shanmugam MS R.Ph. (Age 56)Head of R&D, COO of Novitium Operations & Director Mr. James G. Marken (Age 61)Senior Vice President of Operations & Product Development Comp: $673.23kMs. Meredith W. Cook (Age 49)Senior VP, General Counsel & Corporate Secretary Ms. Krista L. Davis (Age 50)Senior VP & Chief Human Resources Officer Ms. Elizabeth Powell J.D.Chief Compliance Officer & Head of Legal of Rare DiseaseMore ExecutivesKey CompetitorsCatalyst PharmaceuticalsNASDAQ:CPRXConcert PharmaceuticalsNASDAQ:CNCEProgenics PharmaceuticalsNASDAQ:PGNXSelecta BiosciencesNASDAQ:SELBCytomX TherapeuticsNASDAQ:CTMXView All CompetitorsInsiders & InstitutionsOri GutwergSold 2,985 sharesTotal: $199,995.00 ($67.00/share)Stephen P CareySold 5,000 sharesTotal: $317,900.00 ($63.58/share)Chad GassertSold 20,000 sharesTotal: $1.29 M ($64.41/share)Boston PartnersBought 8,762 shares on 5/28/2024Ownership: 0.042%Christopher MutzSold 2,000 sharesTotal: $123,220.00 ($61.61/share)View All Insider TransactionsView All Institutional Transactions ANIP Stock Analysis - Frequently Asked Questions Should I buy or sell ANI Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANIP shares. View ANIP analyst ratings or view top-rated stocks. What is ANI Pharmaceuticals' stock price target for 2024? 4 analysts have issued twelve-month target prices for ANI Pharmaceuticals' shares. Their ANIP share price targets range from $77.00 to $87.00. On average, they anticipate the company's share price to reach $81.00 in the next year. This suggests a possible upside of 28.1% from the stock's current price. View analysts price targets for ANIP or view top-rated stocks among Wall Street analysts. How have ANIP shares performed in 2024? ANI Pharmaceuticals' stock was trading at $55.14 on January 1st, 2024. Since then, ANIP stock has increased by 14.7% and is now trading at $63.24. View the best growth stocks for 2024 here. Are investors shorting ANI Pharmaceuticals? ANI Pharmaceuticals saw a increase in short interest in the month of May. As of May 31st, there was short interest totaling 339,100 shares, an increase of 65.9% from the May 15th total of 204,400 shares. Based on an average daily trading volume, of 153,400 shares, the short-interest ratio is presently 2.2 days. View ANI Pharmaceuticals' Short Interest. When is ANI Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our ANIP earnings forecast. How were ANI Pharmaceuticals' earnings last quarter? ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) issued its quarterly earnings data on Friday, May, 10th. The specialty pharmaceutical company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.79 by $0.16. The specialty pharmaceutical company earned $137.43 million during the quarter, compared to analyst estimates of $125.01 million. ANI Pharmaceuticals had a net margin of 6.87% and a trailing twelve-month return on equity of 17.15%. What ETFs hold ANI Pharmaceuticals' stock? ETFs with the largest weight of ANI Pharmaceuticals (NASDAQ:ANIP) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), First Trust Small Cap Growth AlphaDEX Fund (FYC), SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). What guidance has ANI Pharmaceuticals issued on next quarter's earnings? ANI Pharmaceuticals updated its FY 2024 earnings guidance on Saturday, June, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $520.0 million-$542.0 million, compared to the consensus revenue estimate of $513.1 million. What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO? 5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend. What other stocks do shareholders of ANI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC). Who are ANI Pharmaceuticals' major shareholders? ANI Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.20%), William Blair Investment Management LLC (2.33%), Global Alpha Capital Management Ltd. (1.85%), Kennedy Capital Management LLC (1.00%), Russell Investments Group Ltd. (0.51%) and Principal Financial Group Inc. (0.42%). Insiders that own company stock include Antonio R Pera, Chad Gassert, Christopher Mutz, James G Marken, Jeanne Thoma, Krista Davis, Meredith Cook, Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Ori Gutwerg, Patrick D Walsh, Renee P Tannenbaum, Stephen P Carey and Thomas Haughey. View institutional ownership trends. How do I buy shares of ANI Pharmaceuticals? Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ANIP) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredLike Investing in Big Tech in the Early 2000s?More than a decade after the first Bitcoin was mined, people are finally realizing something very important......Manward Press | SponsoredThe Single Biggest Breakthrough of the Decade Billionaires, Jeff Bezos, Bill Gates, Warren Buffett, and Sir Richard Branson are rallying behind this technol...Porter & Company | SponsoredAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ANI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.